



THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title: Analysis of Gene Variants Previously Associated With Iloperidone Response in Patients With Schizophrenia Who Are Treated With Risperidone

Author(s): Bonnie A. Fijal, PhD; Virginia L. Stauffer, PharmD; Bruce J. Kinon, MD; Robert R. Conley, MD; Vicki Poole Hoffmann, PhD; Michael M. Witte, PhD; Fangyi Zhao, PhD; and John P. Houston, MD, PhD

DOI Number: 10.4088/JCP.10m06507

List of Supplementary Material for the article

1. [eTable 1](#) Study Completion Rates for Risperidone-treated Patients Stratified by Race, Response Status at Week 2, and Genotype
2. [eTable 2](#) LS Mean PANSS Total Scores at Week 2 for Risperidone-treated Patients Stratified by Race, Response Status at Week 2, and Genotype
3. [eTable 3](#) LS Mean PANSS Total Scores at Week 12 for Risperidone-treated Patients Stratified by Race, Response Status at Week 2, and Genotype
4. [eTable 4](#) Change in PANSS Total Score From Baseline to Endpoint, Genotype Frequencies, and p Values for the Difference in Improvement Between Responder and Non-responder Genotypes For SNPs That Were Not Significantly Associated with Improvement in Patients Treated With Risperidone

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eTable 1. Study Completion Rates for Risperidone-treated Patients Stratified by Race, Response Status at Week 2, and Genotype

Characteristic	Completion Rate (%)
	N=145
Race	
African American	65.5 (57/87)
White	69.0 (40/58)
Response status at week 2	
Early responder	48.4 (15/31)
Early non-responder	71.9 (82/114)
Genotype	
NPAS3 rs11851892	
C/C	64.8 (68/105)
C/T	77.1 (27/35)
T/T	40.0 (2/5)
XKR4 rs9643483	
G/G	63.9 (23/36)
G/T	75.4 (43/57)

T/T	59.6 (31/52)
TNR rs875326	
C/C	73.6 (53/72)
C/T	53.6 (30/56)
T/T	82.4 (14/17)
GRIA4 rs2513265	
A/A	62.5 (20/32)
A/T	69.6 (48/69)
T/T	65.9 (29/44)
GFRA2 rs7837682	
C/C	72.7 (8/11)
C/T	64.4 (29/45)
T/T	67.4 (60/89)
NUDT9P1 rs4528226	
G/G	61.8 (21/34)
G/T	73.3 (55/75)
T/T	58.3 (21/36)

eTable 2. LS Mean PANSS Total Scores at Week 2 for Risperidone-treated Patients Stratified by Race, Response Status at Week 2, and Genotype

Characteristic	PANSS Total Score
	LS Mean (SD)
	N=145
Race	
African American	76.2 (11.9)
White	79.0 (14.6)
Response status at Week 2	
Early responder	65.7 (13.8)
Early non-responder	80.5 (10.9)
Genotype	
NPAS3 rs11851892	
C/C	74.8 (13.1)
C/T	76.3 (16.0)
T/T	76.3 (20.3)
XKR4 RS9643483	
G/G	71.8 (12.9)
G/T	76.8 (14.7)

T/T	76.1 (13.7)
TNR RS875326	
C/C	74.7 (16.6)
C/T	76.3 (11.0)
T/T	74.0 (12.7)
GRIA4 rs2513265	
A/A	76.1 (11.0)
A/T	75.4 (15.6)
T/T	74.3 (13.5)
GFRA2 rs7837682	
C/C	86.2 (12.4)
C/T	72.8 (13.1)
T/T	75.3 (14.2)
NUDT9P1 rs4528226	
G/G	78.64 (14.1)
G/T	73.11 (14.4)
T/T	76.63 (12.0)

Abbreviations: LS=least squares; SD=standard deviation

eTable 3. LS Mean PANSS Total Scores at Week 12 for Risperidone-treated Patients Stratified by Race, Response Status at Week 2, and Genotype

Characteristic	PANSS Total Score
	LS Mean (SD)
	N=98
Race	
African American	67.7 (11.2)
White	69.3 (16.2)
Response Status at week 2	
Early responder	58.7 (14.4)
Early non-responder	70.2 (12.5)
Genotype	
NPAS3 rs11851892	
C/C	68.5 (14.5)
C/T	64.9 (11.9)
T/T	54.5 (20.5)
XKR4 rs9643483	
G/G	60.4 (13.1)
G/T	70.2 (12.9)

T/T	67.9 (15.1)
TNR rs875326	
C/C	69.5 (16.1)
C/T	64.7 (9.6)
T/T	65.9 (18.7)
GRIA4 rs2513265	
A/A	68.6 (17.4)
A/T	64.8 (12.1)
T/T	68.7 (14.6)
GFRA2 rs7837682	
C/C	69.0 (5.7)
C/T	67.6 (16.2)
T/T	65.1 (6.8)
NUDT9P1 rs4528226	
G/G	70.8 (18.4)
G/T	65.8 (10.6)
T/T	64.6 (14.2)

Abbreviations: LS=least squares; SD=standard deviation

eTable 4. Change in PANSS Total Score From Baseline to Endpoint, Genotype Frequencies, and *p* Values for the Difference in Improvement Between Responder and Non-responder Genotypes For SNPs That Were Not Significantly Associated with Improvement in Patients Treated With Risperidone.

Gene and SNP		LS Mean Change (SE) in PANSS Total and				<i>p</i> value
Race/Ethnicity	n	Percent of Patients with Each Genotype				
NPAS3 rs11851892		A/A	A/G	G/G	Non-G/G	
All	145	-15.1 (6.1) 3.5%	-23.2 (2.4) 29.7%	-18.2 (1.6) 66.9%	-22.1 (2.2) 33.1%	.20
African American	87	-11.0 (6.1) 4.6%	-18.9 (2.8) 29.9%	-17.3 (1.8) 65.5%	-17.8 (2.6) 34.5%	.37
White	58	-24.7 (16.9) 1.7%	-27.4 (4.3) 29.3%	-17.7 (3.2) 69.0%	-27.2 (4.1) 31.0%	.23
TNR rs875326		A/A	A/G	G/G	Non-A/G	

All	139	-20.2 (2.9)	-21.3 (2.2)	-19.1 (2.1)	-19.2 (1.7)	.32
		18.7%	33.8%	47.5%	66.2%	
African American	83	-17.2 (2.7)	-18.5 (2.0)	-18.9 (3.3)	-17.1 (2.1)	.45
		26.5%	44.6%	28.9%	55.4%	
White	56	-24.1 (7.8)	-33.4 (6.0)	-21.9 (2.8)	-21.8 (2.6)	.07
		7.1%	17.9%	75.0%	82.1%	
GFRA2 rs7837682		G/G	A/G	A/A	Non-A/A	
All	143	-22.1 (5.5)	-17.3 (2.1)	-20.8 (1.7)	-17.9 (2.0)	.50
		5.6%	37.1%	57.3%	42.7%	
African American	85	-13.5 (5.9)	-16.4 (2.1)	-19.9 (2.2)	-15.7 (2.0)	.41
		7.1%	45.9%	47.1%	52.9%	
White	58	-44.5 (11.3)	-16.9 (5.1)	-22.0 (2.8)	-21.1 (4.7)	.24
		3.5%	24.1%	72.4%	27.6%	
NUDT9P1 rs4528226		G/G	G/T	T/T	Non-G/T	

All	145	-23.0 (2.7) 21.4%	-15.7 (1.9) 46.2%	-22.0 (2.2) 32.4%	-22.4 (1.7) 53.8%	.33
African American	87	-19.7 (5.3) 6.9%	-14.2 (2.2) 46.0%	-20.0 (2.1) 47.1%	-20.0 (1.9) 54.0%	.36
White	58	-25.2 (3.5) 43.1%	-17.5 (3.2) 46.6%	-35.0 (7.1) 10.3%	-27.0 (3.2) 53.4%	.27

Abbreviations: LS=least squares; PANSS=Positive and Negative Syndrome Scale; SE=standard error; SNP=single nucleotide polymorphism.